Shield Therapeutics Share Price (STX)

31.00 -0.50 (-1.59%) delayed: 1:00PM GMT
Bid price 30.00 Open price 30.00
Ask price 32.00 Prev close 31.00
High price 30.85 Spread 6.25%
Low price 30.00 Volume 60,939

Register now for FREE live Shield Therapeutics share prices, Shield Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Shield Therapeutics Level 2 Data, indepth research tools and investor commentary for Shield Therapeutics (STX) and other London Stock Exchange equities.

Shield Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Shield Therapeutics share price charts

Shield Therapeutics Share Price Information

Name Shield Therapeutics Epic STX
Sector Pharmaceuticals & Biotechnology ISIN GB00BYV81293
Activites Shield Therapeutics plc is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. Index n/a

Shield Therapeutics Key Numbers

Latest Share Price (p) 31.00 Net Gearing (%) -21.21
Market Capitalisation (£m) 36.67 Gross Gearing (%) 8.37
Shares in issue (m) 116.43 Debt Ratio 0.00
P/E Ratio -1.85 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.09
Dividend Yield (%) 0.00 Price to book value 0.89
Dividend cover (x) 0.00 ROCE (%) -50.93
Earning per share (p) -17.00 EPS Growth (%) -13.33
52 week high / low 115.00 / 15.10 DPS Growth (%) n/a

Shield Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
24/09/2018 BUY Carl Sterritt CEO 88,235
05/10/2017 BUY Carl Sterritt CEO 8,814

More Shield Therapeutics Director Deals >>

Shield Therapeutics Company News

07:00 13/12/2018

US New Drug Application PDUFA date for Feraccru

RNS Number : 3169K Shield Therapeutics PLC 13 December 2018   Shield Therapeutics plc ("Shield" or the "Group") Shield Therapeutics announces the US New Drug Application PDUFA date for Feraccru ®   London, UK, 13 December 2018: Shield Therapeutics plc...

13:10 05/12/2018

Shield Therapeutics partner starts selling iron deficiency treatment UK

Shield Therapeutics said that European distribution partner Norgine had launched its iron deficiency treatment in the UK. Sheild in September licensed the so-called Feraccru treatment to Norgine in most European territories. 'Since announcing the licence agreement in September 2018, we have...

10:04 05/12/2018

UK launch of Feraccru

RNS Number : 5186J Shield Therapeutics PLC 05 December 2018   Shield Therapeutics plc ("Shield" or the "Group") Shield Therapeutics notes UK launch of Feraccru® by Norgine   London, UK, 5 December 2018: Shield Therapeutics plc (LSE:STX), a commercial stage,...

More Shield Therapeutics Company News >>

Register now for FREE Shield Therapeutics company news

Shield Therapeutics Share Price Discussions

more than 1 year ago

Seagate Technology (STX)

traded on Nasdaq - anyone holding? PE of 4 and company on a buy back mission

Register now for FREE Shield Therapeutics share price discussions